Advertisement
Advertisement
July 16, 2019
Corindus' CorPath GRX Approved for Neurovascular Interventions in Australia and New Zealand
July 17, 2019—Corindus Vascular Robotics, Inc. announced that it received approval from the Australian Therapeutic Goods Administration to commercialize its CorPath GRX system for neurovascular interventions in Australia and New Zealand.
The CorPath GRX system is already approved for percutaneous coronary and peripheral vascular interventions in the region. The CorPath GRX system is distributed in Australia and New Zealand by LifeHealthcare.
In March 2019, Corindus received CE Mark approval to commercialize CorPath GRX for neurovascular interventions in 33 countries in Europe and the company plans to initiate clinical cases with select partners in Europe as early as this summer, stated the company.
Advertisement
Advertisement
